**Abstract**

**Purpose**: Omega-3 polyunsaturated fatty acids (PUFAs), which include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are important to mental health and physical health. In recent years, A lower level of omega-3 PUFAs has been proposed to be linked with mental disorders that are schizophrenia, depression, dementia, bipolar disorder and attention-deficit / hyperactivity disorder (ADHD). Medications, such as atomoxetine (ATX) and methylphenidate (MPH), improve daily living performance of patients with ADHD. However, Psychotropic drug are not preferred by some patients or families. If a success in achieving a therapeutic effect with the omega-3 fatty acids, that may be compensated from the dietary supplementation.

We report as a pre-stage of replacement therapy study on omega*-*3 PUFA, since examined for blood PUFA's concentration youth ADHD patient.

**Methods**: At Nagasaki University Hospital Department of Psychiatry, on November 2010 to May 2015, The subject were ADHD patients aged 9 to 18 years (N = 28). From their medical records of PUFA in blood serum EPA, DHA, Arachidonic acid (AA), date of birth, drug treatment (ATX or MPH), The Global Assessment of Functioning (GAF), Clinical Global Impressions (CGI), ADHD-RS4 were investigated.

**Results**: In ADHD patients at the Nagasaki University Hospital, it has been clear that the blood omega-3 PUFAs concentration is significantly lower (P\<0.01). On the other hand, AA that are classified as omega-6 PUFAs concentration is significantly higher (P\<0.01). In addition, From the association with the GAF scores and blood concentration of EPA.

**Conclusions**: The youth ADHD patients has revealed that the balance of omega-3 and omega-6 PUFAs are collapsed, and the height of the blood EPA levels may relate to these therapeutic sensitivity. From the above fact**s,** We expected to have the usefulness of treatment with omega-3 unsaturated fatty acid supplementation on youth ADHD patients.
